Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03462212
Title Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25)
Acronym MITO25
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Ospedale Mater Salutis RECRUITING Legnago Italy Details
ASST Grande Ospedale Metropolitano Niguarda RECRUITING Milan Italy Details
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale RECRUITING Naples Italy Details
Azienda Ospedaliera di Perugia RECRUITING Perugia Italy Details
Nuovo Ospedale degli Infermi RECRUITING Ponderano Italy Details
Fondazione Policlinico Universitario A.Gemelli IRCCS RECRUITING Rome 00168 Italy Details
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS RECRUITING Turin Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field